Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2010-09-27 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Novartis's investigational pre-pandemic influenza vaccine Aflunov. The document is informational and regulatory in nature, providing updates on regulatory progress and product development, but it does not contain financial statements, earnings data, or detailed financial analysis. It is not an annual or interim report, nor is it a transcript, audit report, or capital update. The document is a regulatory announcement filed on Form 6-K, which is typically used for current reports by foreign private issuers to disclose material information. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, indicating it is a full report rather than a brief announcement, but the content is still regulatory and informational rather than a financial report.
2010-09-27 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. The content primarily announces a transaction where Novartis sells US rights to a pharmaceutical product (Enablex) to Warner Chilcott. It includes details of the deal, payment terms, regulatory considerations, and forward-looking statements. There are no financial statements or detailed financial performance data included. The document is an announcement of a corporate transaction and financing-related update rather than a full financial report or earnings release. Given the nature of the content focusing on a capital transaction and licensing rights sale, the most appropriate classification is Capital/Financing Update (CAP). The document length (7996 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2010-09-24 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing FDA approval of a new drug, Gilenya, including detailed information about the drug, clinical trial results, safety information, and forward-looking statements. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a transcript, audit report, or management change announcement. It is a regulatory filing providing material information to investors about a significant corporate event (FDA approval of a drug). The document length is substantial (15,000 characters), indicating it is not a brief announcement but a full disclosure document. Therefore, the best classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2010-09-23 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release announcing the results of a Phase III clinical trial for a drug (SOM230) for Cushing's disease. It includes detailed clinical trial results, safety data, and plans for regulatory filing. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information to investors about clinical trial results and future regulatory plans. Form 6-K filings are generally classified under Regulatory Filings (RNS) as they are miscellaneous reports by foreign issuers that do not fit other categories. The document is substantive and lengthy (15,000 characters), so it is not a mere announcement of a report publication. Therefore, the best classification is Regulatory Filings (RNS).
2010-09-23 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release about clinical study results for a pharmaceutical product (Onbrez Breezhaler) and does not contain financial statements or detailed financial analysis. It is a regulatory announcement providing information to investors but not a full financial report or earnings release. The document length is 13,429 characters, which is substantial but the content is a press release rather than a financial report. There is no indication of it being an earnings release, annual or interim report, or other specific financial filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2010-09-20 English
MAIN DOCUMENT DESCRIPTION
Director's Dealing
2010-09-16 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.